Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease

Stem Cell Research and Therapy

Volumn 8, Issue 1, 2017, Pages

  De Witte, Samantha F H ^a   Merino, Ana M ^a   Franquesa, Marcella ^a   Strini, Tanja ^a   Van Zoggel, Johanna A A ^a   Korevaar, Sander S ^a   Luk, Franka ^a   Gargesha, Madhu ^d   O'Flynn, Lisa ^b   Roy, Debashish ^d   Elliman, Steve J ^b   Newsome, Philip N ^c   Baan, Carla C ^a   Hoogduijn, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Orbsen Therapeutics Ltd   (Ireland)

^c University Hospital Birmingham NHS Foundation Trust   (United Kingdom)

^d BIOINVISION INC   (United States)

Author keywords

Immunogenic; Immunomodulatory; Mesenchymal stromal cell; Optimising

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROSTAGLANDIN E2; PYRIDOXINE; RETINOIC ACID; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LIVER DISEASE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STROMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; T LYMPHOCYTE; TREATMENT RESPONSE; UMBILICAL CORD BLOOD CELL; ANIMAL; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; GENETICS; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; PATHOLOGY; TRANSPLANTATION; UMBILICAL CORD;

ANIMALS; CELL PROLIFERATION; CYTOKINES; HUMANS; INFLAMMATION; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LIVER DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; UMBILICAL CORD;

EID: 85020448934     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-017-0590-6     Document Type: Article

References (46)

1. Luk F, et al. Efficacy of immunotherapy with mesenchymal stem cells in man: a systematic review. Expert Rev Clin Immunol. 2015;11(5):617-36.
2. Gonzalez-Rey E, et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58(7):929-39.
3. Bouffi C, et al. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One. 2010;5(12):e14247.
4. Rafei M, et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol. 2009;182(10):5994-6002.
5. Le Blanc K, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579-86.
6. Forbes GM, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014;12(1):64-71.
7. Zhang Z, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 2012;27 Suppl 2:112-20.
8. El-Ansary M, et al. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev Rep. 2012;8(3):972-81.
9. Amin MA, et al. Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study. Clin Transplant. 2013;27(4):607-12.
10. Xu LM, et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. J Gastroenterol Hepatol. 2014;29(8):1620-8.
11. Liu X, et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant. 2014;23(9):1087-98.
12. Shi M, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 2012;1(10):725-31.
13. El-Ansary M, et al. Phase I Trial: Mesenchymal stem cells transplantation in end stage liver disease. Stem Cell. 2010;1(2):22-33.
14. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499-506.
15. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: Cytokines and factors. Am J Reprod Immunol. 2012;67(1):1-8.
16. English K, et al. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25Highforkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009;156(1):149-60.
17. Engela AU, et al. On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol. 2012;3:126.
18. Meisel R, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103(12):4619-21.
19. Popp FC, et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol. 2008;20(1-2):55-60.
20. Harris SG, et al. Prostaglandins as modulators of immunity. Trends Immunol. 2002;23(3):144-50.
21. Nemeth K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15(1):42-9.
22. Rafei M, et al. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther. 2009;17(10):1799-803.
23. Luz-Crawford P, et al. Mesenchymal stem cell-derived interleukin 1 receptor antagonist promotes macrophage polarization and inhibits B cell differentiation. Stem Cells. 2016;34(2):483-92.
24. Augello A, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol. 2005;35(5):1482-90.
25. Blanc KL, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31(10):890-6.
26. Crop MJ, et al. Human mesenchymal stem cells are susceptible to lysis by CD8+ T cells and NK cells. Cell Transplant. 2011;20(10):1547-59.
27. Sotiropoulou PA, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006;24(1):74-85.
28. Cho PS, et al. Immunogenicity of umbilical cord tissue derived cells. Blood. 2008;111(1):430-8.
29. Eggenhofer E, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012;3:297.
30. Fischer UM, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683-92.
31. da da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119:2204-13.
32. Kuci S, et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica. 2010;95(4):651-9.
33. Campioni D, et al. A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. Cytometry Part B Clin Cytometry. 2009;76(3):225-30.
34. Beavis PA, et al. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 2012;33(5):231-7.
35. Nasef A, et al. Selected Stro-1-enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int J Lab Hematol. 2009;31(1):9-19.
36. Bensidhoum M, et al. Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood. 2004;103(9):3313-9.
37. Prasanna SJ, et al. Pro-inflammatory cytokines, IFN(gamma) and TNF(alpha), influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One. 2010;5(2):e9016.
38. Sivanathan KN, et al. Interleukin-17A-induced human mesenchymal stem cells are superior modulators of immunological function. Stem Cells. 2015;33(9):2850-63.
39. de Witte SF, et al. Toward development of imesenchymal stem cells for immunomodulatory therapy. Front Immunol. 2015;6:648.
40. Roemeling-van Rhijn M, et al. Effects of hypoxia on the immunomodulatory properties of adipose tissue-derived mesenchymal stem cells. Front Immunol. 2013;4:203.
41. Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7.
42. Hoogduijn MJ, et al. Effects of freeze-thawing and intravenous infusion on mesenchymal stromal cell gene expression. Stem Cells Dev. 2016;25(8):586-97.
43. Luz-Crawford P, et al. Mesenchymal stem cells generate a CD4 + CD25 + Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther. 2013;4(3):65.
44. Giuliani M, et al. Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood. 2011;118(12):3254-62.
45. Poggi A, et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol. 2005;175(10):6352-60.
46. Gotherstrom C, et al. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy. 2011;13(3):269-78.